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Introduction: Mutant BRAF is a driver oncogene found in 2% of 
lung adenocarcinomas and represents a target for therapy. We exam-
ined the clinical characteristics and course of patients with lung ade-
nocarcinomas harboring BRAF mutations.
Methods: We identified patients with lung adenocarcinomas harbor-
ing BRAF mutations between 2009 and 2013 detected using a mass 
spectrometry–based polymerase chain reaction genotyping assay of 
hot-spot mutations involving codons corresponding to amino acids 
V600, D594, and G469 of BRAF. Patient characteristics and treat-
ment outcomes were analyzed. Overall survival (OS) was compared 
with stage-matched patients with KRAS and EGFR mutant lung 
adenocarcinomas.
Results: Sixty-three patients were diagnosed with BRAF mutant lung 
adenocarcinomas between 2009 and 2013 (V600, 36; non-V600, 27). 
The majority of patients with BRAF mutations were smokers (92%), 
although patients with V600 mutations were more likely to be light/
never-smokers compared with patients with non-V600 mutations 
(42% versus 11%; p = 0.007). Of the 32 patients with early-stage 
disease, six (19%; 95% confidence interval 7%–36%) developed sec-
ond primary lung cancers harboring KRAS mutations. Patients with 
advanced V600 mutant lung adenocarcinomas had a better survival 
from diagnosis compared with those with non-V600 mutant lung 
adenocarcinomas (3-year OS: 24% versus 0%; p < 0.001).
Conclusions: This is the largest series of patients with BRAF mutant 
lung cancers described. Most patients were heavy smokers. Nineteen 
percent of patients with early-stage BRAF mutant lung cancers 
developed second primary lung cancers harboring KRAS mutations. 
Patients with advanced lung adenocarcinomas harboring V600 muta-
tions have an improved OS compared with those with non-V600 
mutations.
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The discovery of targetable driver mutations in a subset of patients with lung adenocarcinomas has transformed the 
therapeutic approach to patients with lung cancers. Treatment 
with epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors (gefitinib, erlotinib, and afatinib) improves 
response rates and progression-free survival compared with 
cytotoxic chemotherapy for patients with advanced-stage lung 
adenocarcinomas harboring EGFR mutations.1–5 Similarly, in 
patients with lung cancers defined by the anaplastic lymphoma 
kinase gene rearrangement, crizotinib prolongs progression-
free survival compared with docetaxel or pemetrexed.6,7
Activating molecular alterations have also been iden-
tified in genes such as BRAF, KRAS, HER2, FGFR2, RET, 
ROS1, and PIK3CA that could potentially be targeted in lung 
cancers.8,9 BRAF is a serine/threonine kinase downstream of 
RAS in the RAS–RAF–MEK–ERK signaling pathway. When 
activated by mutations, BRAF phosphorylates MEK to pro-
mote cell growth, proliferation, and survival. Somatic muta-
tions in BRAF are found in several different cancers, including 
melanoma, papillary thyroid cancers, colorectal cancers, ovar-
ian carcinomas, and lung cancers. The clinical significance of 
V600 BRAF mutations is highlighted by the demonstrated 
activity of BRAF and/or MEK inhibitors in patients with 
BRAF mutant melanoma.10–12
In lung cancers, preclinical work has confirmed a role 
of mutant BRAF in the development and maintenance of lung 
adenocarcinomas.13,14 BRAF mutations are detected in 2% of 
lung cancers. Unlike melanomas in which the vast majority 
of BRAF mutations occur at V600, only approximately 50% 
of BRAF mutant lung adenocarcinomas harbor V600 muta-
tions, with the rest of the cases harboring non-V600 mutations 
in exons 11 and 15.15–19 This has clear therapeutic implica-
tions because non-V600 mutant BRAF kinases seem to be 
resistant to BRAF-targeted therapies but may be sensitive to 
pharmacologic inhibition of MEK through the transactivation 
of CRAF.20,21 The prognostic significance of different BRAF 
mutations has not been evaluated in patients with lung cancers.
Several previous groups have begun to define the prev-
alence, distribution, and prognosis of BRAF mutations in 
patients with lung adenocarcinoma.16–19 These studies have 
been limited by relatively small numbers of patients. As part 
of a multiplex assay, we have routinely tested lung adeno-
carcinomas for the presence of hot-spot mutations in BRAF 
since 2009 and have collected the largest series of patients 
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to date.22,23 In this article, we report the characteristics of 
patients with lung adenocarcinomas harboring BRAF muta-
tions and describe their clinical course. We hypothesized that 
patients with V600 mutant tumors would have a significantly 
prolonged survival compared with patients with non-V600 
mutant tumors.
PATIENTS AND METHODS:
Study Patients
We identified patients with lung cancers harboring BRAF 
mutations detected between 2009 and 2013. Patient demo-
graphics and characteristics, including age, sex, race, stage at 
initial diagnosis of BRAF mutant disease, date of resection, 
treatment history, and smoking history, were recorded. Stage 
was determined according to the American Joint Committee 
on Cancer staging system, 7th edition. Patients were followed 
from the date of cancer diagnosis until date of death or last 
available follow-up. This cohort of patients includes the 18 
patients described by Paik et al.16 A comparison group of 
consecutive EGFR and KRAS mutant patients diagnosed and 
treated at Memorial Sloan Kettering during the same calendar 
period was used for comparison.
Genotype Analysis
BRAF mutation analysis was performed using a 
MassARRAY system, a technique based on matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry 
(Sequenom, San Diego, CA).24,25 Amplification and extension 
primers were designed using the Sequenom Assay Designer 
v3.1 software to target mutations involving codons V600, 
D594, and G469 of BRAF. The primer sequences are listed 
in Supplementary Table S1 (Supplemental Digital Content, 
http://links.lww.com/JTO/A701). EGFR exon 19 deletions 
and exon 21 L858R amino acid substitutions were identified 
by previously reported methods.26,27 KRAS codon 12 and 13 
mutations were identified by mass spectrometry–based geno-
typing or direct sequencing.
Statistical Analysis
Fisher’s exact and Wilcoxon rank-sum tests were used 
to compare the demographics and clinical characteristics 
between patients in the V600 and non-V600 mutated sub-
groups. Overall survival (OS) was either calculated from 
the date of resection (for early-stage disease) or from date 
of pathologic diagnosis (for stage IIIb or stage IV disease) 
to death. Patients who did not die during the study time were 
censored at the time they were last confirmed alive.
Patients became eligible for the study at the time of 
their molecular diagnosis for BRAF mutation. In some cases, 
there was a non-negligible amount of time between resection/
pathologic diagnosis (when follow-up started) and BRAF status 
determination. To account for this delay and avoid any potential 
length time bias associated, all analyses were performed using 
left truncation (or delayed entry) techniques. Consequently, OS 
was estimated using the Kaplan–Meier method, with survival 
probabilities calculated conditional on patients having survived 
until the date of their molecular testing. Group comparisons 
were performed using the log-rank test. A two-sided p value 
less than 0.05 was considered statistically significant. Statistical 
analyses were performed using the “survival” package in R 
(version 3.0.1; R Development Core Team) and SAS statistical 
software (SAS Institute, Inc, Cary, NC).
RESULTS
Patient Characteristics:
Sixty-three patients with BRAF mutant lung adenocar-
cinomas were identified with a median follow-up time from 
diagnosis of 42 months for early-stage disease and 18 months 
for advanced-stage disease. Thirty-six patients had a BRAF 
V600 mutation and 27 had a non-V600 mutation. Patient char-
acteristics are summarized in Table 1. There was no significant 
difference in age, sex, or stage at initial diagnosis between 
patients with V600 and non-V600 mutations. Patients with 
V600 mutant tumors were more likely to be light/never-smok-
ers compared with patients with tumors harboring non-V600 
mutations (p = 0.007).
BRAF Genotypes
Five BRAF mutation genotypes were identified: V600E 
(57%), G469A (22%), D469V (13%), D594G (6%), and 
V600M (2%). Figure 1 demonstrates the distribution of BRAF 
genotypes based on early-stage and advanced-stage disease. 
No tumor with a BRAF mutation had a concomitant mutation 
in EGFR, KRAS, or a rearrangement in ALK.
Second Lung Cancers
Of the 32 patients with early-stage disease, six (19%) 
developed metachronous or synchronous second primary 
lung cancers harboring KRAS mutations (Table 2), one patient 
developed metachronous squamous lung cancer, one patient 
developed EGFR L895R mutant lung cancer, and one patient 
developed a metachronous lung cancer for which molecu-
lar testing was not performed. All six patients with second 
primary KRAS mutant lung cancers were former or current 
smokers who smoked a median of 28 pack-years (range, 24–
60 pack-years).
Clinical Outcomes of Patients with and 
without BRAF Mutant Lung Cancer
The 3-year OS after resection of early-stage lung cancer 
was similar for patients with V600 mutant tumors compared 
with non-V600 mutant tumors (67% versus 75%; p = 0.42; 
Fig. 2A). Three patients with early-stage disease were excluded 
from the analysis because they did not undergo resection. In 
patients with stage IIIb or IV BRAF mutant lung adenocar-
cinomas, those with V600 mutations had a longer 3-year OS 
compared with patients with non-V600 mutations (24% ver-
sus 0%; p < 0.001; Fig. 2B). Four patients with advanced-stage 
BRAF mutant lung adenocarcinomas were excluded from this 
survival analysis because they had molecular testing after the 
date of their last follow-up.
We then compared OS of patients with BRAF V600 
mutant disease to patients with KRAS or EGFR mutations dur-
ing the same time period. For early-stage disease, no difference 
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was found in OS based on genotype (p = 0.23; Fig. 3A). In 
patients with advanced-stage disease, 3-year OS was signifi-
cantly longer for the EGFR mutant group compared with the 
KRAS group (38% versus 13% for EGFR and KRAS patients, 
respectively; p < 0.001; Fig. 3B). The OS for patients with 
BRAF mutations was numerically intermediate between those 
with KRAS and EGFR mutations, but not statistically dis-
tinct from either genotype-defined cohort. Only half of those 
patients with BRAF V600 mutations received BRAF-targeted 
therapy, whereas 94% of patients with EGFR mutations in this 
cohort received EGFR tyrosine kinase inhibitors.
TABLE 1.  Patient Characteristics
Mutant BRAF All (n = 63) V600 (n = 36) Non-V600 (n = 27) p
Median age, years 65 64 66 0.72
  Range (33–85) (48–79) (33–85)
Sex 0.97
  Female 34 (54%) 19 (53%) 15 (56%)
  Male 29 (46%) 17 (47%) 12 (44%)
Smoking history 0.007
  Never-smokers 5 (8%) 3 (8%) 2 (7%)
  ≤15 pack-years 13 (21%) 12 (33%) 1 (4%)
  >15 pack-years 45 (71%) 21 (58%) 24 (89%)
Histology
 Adenocarcinoma 100% 100% 100%
Stagea 0.054
  I 17 (27%) 9 (25%) 8 (30%)
  II 4 (6%) 2 (6%) 2 (7%)
  IIIa 11 (17%) 3 (8%) 8 (30%)
  IIIb 4 (6%) 2 (6%) 2 (7%)
  IV 27 (43%) 20 (56%) 7 (26%)
Race 0.48
  White, non-Hispanic 55 (87%) 30 (83%) 25 (93%)
  Asian 3 (5%) 2 (6%) 1 (4%)
  Black 3 (5%) 2 (6%) 1 (4%)
  White, Hispanic 2 (3%) 2 (6%) 0 (0%)
aStage at initial non–small-cell lung cancer diagnosis, American Joint Committee on Cancer (AJCC) staging system 7th edition.
FIGURE 1.  Frequency of BRAF mutations in non–
small-cell lung cancer (NSLCC). A, Stages I–IIIa, 
n = 32. B, Stage IIIb/IV, n = 31.
TABLE 2.  Secondary Lung Cancer with KRAS Mutations
Patient
BRAF  
Mutation Type of Second Lung Cancer
Months 
between
1 G469A Metachronous with KRAS G12D 43 mo
2 G469A Metachronous with KRAS G13C 15 mo
3 V600E Metachronous with KRAS G12V 50 mo
4 G469V Synchronous with KRAS G12C –
5 V600E Synchronous with KRAS G12C –
6 G469A Synchronous with KRAS G12C –
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Response to BRAF Inhibitors:
Ten of the 20 patients with advanced-stage BRAF V600E 
mutant lung cancers were treated with BRAF inhibitors at some 
point during their treatment course. Sixty percent had a partial 
response, 30% had stable disease, and 10% had progressive 
disease per Response Evaluation Criteria in Solid Tumors. Half 
(5/10) of these patients have remained on therapy for over 6 
months, whereas three remain on therapy for over 1 year.
DISCUSSION
Patients with BRAF mutant lung cancers represent a 
distinct subset of patients with lung cancers that may ben-
efit from BRAF-targeted therapy. Building on the success of 
BRAF inhibitors in patients with BRAF V600 melanomas, 
similar activity has recently been demonstrated in patients 
with lung cancers. An interim analysis of a phase II study 
of dabrafenib in patients with BRAF V600 mutant lung 
adenocarcinomas showed an overall response rate of 54% 
with the longest duration of response of 49 weeks thus far.28 
To more fully understand the underlying biology of these 
patients, it is important to investigate the clinical charac-
teristics of these patients and the prognostic significance of 
these mutations.
This is the largest series of patients with BRAF mutant 
lung cancers reported to date. Similar to previous studies, we 
found that BRAF mutations occurred most often in smokers. 
The large number of patients in this analysis allowed us to 
observe that smoking status differs significantly according to 
BRAF mutation type, with V600 mutations occurring prefer-
entially in light/never-smokers. These results are similar to 
what was presented by Marchetti et al17 who found that BRAF 
V600 mutations were more frequent in light/never-smokers. 
No other clinical profile emerged in our study in association 
with BRAF-positive tumors. We did not find an association 
between sex, age, race, or stage at first diagnosis of lung ade-
nocarcinoma and BRAF mutation type.
FIGURE 2.  Overall Survival of BRAF Mutant Lung Cancer. A, 
Stage I–IIIa resected lung cancers. Three patients with early-
stage disease were excluded from the analysis because resec-
tion was not performed. B, Stage IIIb–IV lung cancers. Four 
patients were excluded from the analysis because molecular 
testing was performed after the date of last follow-up.
FIGURE 3.  Overall survival of BRAF V600 vs other lung 
adenocarcinoma genotypes. A, Stage I -IIIa resected lung 
cancers. One patient with early-stage BRAF-V600 lung cancer 
was excluded from the analysis as resection was not performed. 
(BRAF V600 vs. EGFR: p=0.48; BRAF V600 vs. KRAS: p=0.88; EGFR 
vs. KRAS: p=0.093) B, Stage IIIb -IV unresected lung cancers. 
Two patients with BRAF-V600 lung cancers were excluded from 
the analysis as molecular testing was performed after the date 
of last follow-up. (BRAF V600 vs. EGFR:  p=0.25; BRAF V600 vs. 
KRAS: p=0.12; EGFR vs. KRAS: p <0.001).
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In regard to BRAF mutation genotype, we confirmed the 
finding that non-V600 mutations are more common in lung 
cancers than in melanomas. The high incidence of non-V600 
mutations has important clinical consequences because cur-
rent second-generation RAF inhibitors such as dabrafenib and 
vemurafenib are most active in V600 mutant kinases. Third-
generation BRAF inhibitors and MEK1/2 inhibitors may be 
more effective in non-V600 mutations, which represented 43% 
of the patients in our series, and current clinical trials are ongo-
ing. Unlike Cardarella et al and Marchetti et al, we did not have 
any tumors harboring concurrent BRAF mutations and KRAS 
or EGFR mutations, suggesting that these are likely rare events. 
This is consistent with the prospective Lung Cancer Mutation 
Consortium which showed that only three of 1007 tumors ana-
lyzed had a BRAF mutation and a second oncogenic driver.29
In our series, 19% of patients with early-stage BRAF 
mutant disease had a metachronous or synchronous second 
primary lung cancers harboring a KRAS mutation. Each of 
the six patients with second primary lung cancers were heavy 
smokers, which may explain the co-occurrence of these can-
cers. This finding emphasizes the importance of repeating 
molecular studies to distinguish between “de novo” lung can-
cers and recurrence/metastasis because there may be critical 
treatment and prognostic implications.
We further showed that patients with advanced V600 
mutant lung cancers have an improved OS compared with non-
V600 mutant lung cancers and similar survival to EGFR and 
KRAS mutant lung cancers. In contrast, it has been previously 
suggested by Marchetti et al that V600 mutations may have 
a worse prognosis compared with BRAF wild-type tumors. It 
is interesting to note that in our series, 10 of 20 patients with 
stage IV BRAF V600 mutations received an agent targeting 
BRAF as part of routine care or as part of a clinical trial. This 
may have altered the natural history of this patient population 
and improved OS, although this is clearly speculative. The out-
comes of patients treated with BRAF inhibitors are now being 
determined as part of ongoing studies. Furthermore, because 
patients with BRAF V600 tumors were more likely to be light/
never-smokers than those with non-V600 tumors, the effects of 
cigarette smoking may have had an impact on survival.30
As a retrospective study of patients pursing their care at 
a single site, there are some limitations to our analysis. BRAF 
mutations were detected using a platform that identified only 
a limited number of BRAF point mutations. We note that other 
BRAF mutations in lung adenocarcinomas have been identified, 
including mutations in amino acids 421, 439, 459, 466, 471, 
595, 597, 604, and 606.31,32 However, these individual mutations 
represent just 1% to 3% of all BRAF mutations reported. As the 
number of cases of BRAF mutant lung cancers is relatively small, 
larger studies are needed to extend and confirm our results.
In conclusion, our data show that both BRAF non-V600 
and V600 mutant lung adenocarcinomas are more common 
in smokers but can be identified in never-smokers and light 
smokers. Among patients with BRAF mutant lung cancers, the 
incidence of non-V600 BRAF mutations is 43%. Nineteen per-
cent of patients with early-stage BRAF mutant disease have a 
metachronous or synchronous second primary lung cancer har-
boring a KRAS mutation, possibly secondary to a similar risk 
factor of cigarette smoking. Repeat biopsies and molecular test-
ing should be routine for such patients. Patients with advanced 
V600 mutant lung cancers have a prolonged OS compared with 
non-V600 mutant lung cancers. BRAF-directed therapies have 
promising clinical activity in these patients, and various agents 
are currently being tested in the clinic that can potentially 
expand the number of candidates eligible for targeted therapy.
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